Details:
The OLX702A program is based on compelling human genetic evidence which suggests that knockdown of this target may reduce liver fat, inflammation, and fibrosis and protect against liver-related mortality.
Lead Product(s): OLX702A
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OLX702A
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Lead Product(s): Nanocyclix Drug Candidates
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Oncodesign
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2021
Details:
OLX702A, an investigational RNAi therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). OliX will also present its pipeline OLX101A for hypertrophic scars, OLX104C for hair loss, OLX301A/D for age-related macular degeneration and subretinal fibrosis.
Lead Product(s): OLX702A
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OLX702A
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2021
Details:
LISCure Biosciences will receive Mayo Clinic's know-how to establish a new drug, LB-P8, development of NASH program. As part of the agreement, Mayo Clinic will become a shareholder in LISCure, the first Korean biotech company receiving equity investment from Mayo Clinic.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 27, 2021
Details:
LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.
Lead Product(s): LB-P8
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LB-P8
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 26, 2021